F-1/A: Cuprina Holdings Eyes Nasdaq Listing with $[] Million IPO, Resale Offering

Cuprina Holdings (Cayman) Limited files for an initial public offering of 2,500,000 Class A Ordinary Shares, alongside a resale offering of 1,500,000 Class A Ordinary Shares by existing shareholders, seeking a Nasdaq listing under the symbol CUPR.

Summary

• Cuprina Holdings (Cayman) Limited is planning an initial public offering (IPO) of 2,500,000 Class A Ordinary Shares.
• The company intends to list its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol CUPR.
• The IPO price is expected to be between US$[] and US$[] per share.
• Concurrently, certain existing shareholders, Ms. Dorea Quek En Qi and Mr. Bryan Teo Ying Jie, are offering 1,500,000 Class A Ordinary Shares in a resale offering.
• Cuprina Holdings will not receive any proceeds from the resale offering.
• The company is a Singapore-based biomedical and biotechnology company focused on chronic wound care and cosmeceuticals.
• Cuprina's revenue for 2023 was S$100,773 (US$76,424), with a net loss of S$1,119,555 (US$849,048).
• Network 1 Financial Securities, Inc. is acting as the underwriter for the offering.
• The underwriters have an option to purchase up to [] additional Class A Ordinary Shares to cover over-allotments.
• Upon completion of the offering, Cuprina Holding Pte. Ltd. will control more than 50% of the voting power, making Cuprina Holdings a controlled company under Nasdaq rules.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is pursuing growth opportunities and has innovative products, it also faces financial challenges and risks. The sentiment is neutral, reflecting both positive and negative aspects.

Positives

• The company has strategic plans to expand sales and establish physical operations in Southeast Asia, the Middle East, and mainland China.
• Cuprina has attained ISO 13485:2016 standards for its manufacturing facility in Singapore.
• The company is working towards obtaining compliance with 21 CFR Part 820 to secure FDA 510(k) clearance for its chronic wound care products.
• The company has access to innovative technology in developing pipeline products through collaborations with research universities.
• The company is committed to sustainability by utilizing materials derived from natural sources and valorizing waste streams.

Negatives

• The company has a history of losses and expects to incur losses in the future.
• The company recorded net current liabilities as of December 31, 2021, 2022 and 2023.
• The company had net operating cash outflows for the years ended December 31, 2021, 2022 and 2023.
• The company's independent registered public accounting firm expressed substantial doubt regarding its ability to continue as a going concern.

Risks

• The company's business and future growth prospects rely on industry development and consumer demand for its products.
• The company's revenue growth for a particular period is difficult to predict, and a shortfall in forecasted revenues may harm its operating results.
• The company may not be able to develop new products that are competitive or successful in the markets it has entered or plans to enter, in a timely manner or at all.
• The development and sale of certain of the company's pipeline products are heavily dependent on certain agreements with R&D partners, and the termination of any of these agreements could harm its business.
• The company may be found to infringe on or violate the intellectual property rights of others.
• The company is subject to various governmental regulations relating to the labeling, marketing and sale of its products.
• The company is dependent on its key management and skilled personnel for its continued success and growth.

Future Outlook

The company has strategic plans in place for the second half of 2024 and 2025 to expand its sales and establish physical operations in several key regions, including Southeast Asia, the Middle East, and mainland China. The company also plans to explore the possibility of developing a range of potential cosmeceutical product candidates incorporating bullfrog collagen with a view to making them commercially available between 2024 and 2028, subject to the progress of the relevant R&D work.

Industry Context

The company operates in the growing chronic wound care and cosmeceutical markets, driven by an aging population and increasing prevalence of comorbidities. The company's focus on sustainable, nature-derived materials aligns with increasing consumer demand for environmentally responsible products.

Comparison to Industry Standards

• The document does not provide enough information to compare Cuprina Holdings to industry standards.
• To assess Cuprina's performance against industry benchmarks, we would need to compare its financial metrics (revenue growth, profit margins, R&D spending) to those of its competitors.
• Competitors in the wound care market include Smith & Nephew, ConvaTec, and Mlnlycke Health Care.
• Comparable companies in the cosmeceutical market include Giant Biogene, Guangzhou Trauer Biotechnology Co. Ltd., and Shanxi Jinbo Biopharmaceutical Ltd.

Related Party Transactions

• The company has engaged in various transactions with related parties, including loans, management fees, and share subscriptions.
• Cuprina Holding Pte. Ltd. has provided significant financial assistance to the company for working capital purposes.
• One of the ultimate beneficial owners, Jimmy Lee Peng Siew, has provided advances to the company for working capital purposes, which are due by June 30, 2024, or upon completion of the IPO.

Stakeholder Impact

• Shareholders will experience dilution as a result of the IPO.
• The company's ability to execute its growth strategy will impact its employees, customers, and suppliers.
• The company's financial performance will affect its ability to repay its creditors.

Next Steps

• The company intends to list its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol CUPR.
• The company expects to complete the submission process for FDA 510(k) clearance in the second half of 2024 and expects to receive a 510(k) clearance by the end of 2024, subject to FDA enquiries or clarifications.
• The company plans to commence the registration of MEDIFLY products in Southeast Asian jurisdictions in the second half of 2024.
• The company plans to commence clinical trials in Singapore to test the clinical safety and efficacy of its bullfrog sponge dressing in the second half of 2024.

Key Dates

Keywords

IPO, initial public offering, Cuprina Holdings, Class A Ordinary Shares, Nasdaq, wound care, biotechnology, medical devices, cosmeceuticals